Project Grant R01HD122957
- The National Institute of Child Health and Human Development awarded Pennsylvania State University (Penn State Milton S. Hershey Medical Center) $1,324,709 on September 10, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct direct measurement of Rh D sensitization following bleeding in pregnancy less than 12 weeks gestation. The research addresses the clinical utility of Rh immunoglobulin (RhIG) administration during early pregnancy...
- The National Institute of Child Health and Human Development awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, $170,851 on June 1, 2026, for a project grant under the Child Health and Human Development Extramural Research program (CFDA 93.865). The recipient will engage stakeholders to optimize an evidence-based transdiagnostic sleep and circadian intervention for autistic adults ages 18–65. Aim 1 involves iteratively adapting the Transdiagnostic...
- The National Institute of Child Health and Human Development awarded The Pennsylvania State University $470,816 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate molecular and metabolic mechanisms governing secretory activation and milk volume in mothers with infants in the neonatal intensive care unit. The research uses transcriptomic and biochemical analysis of inflammatory and lipid metabolism pathways to identify biological...
- Federal Project Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded The Pennsylvania State University a $428,208 project grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) beginning September 12, 2025, with completion targeted for August 31, 2027. The project develops milk protein-based amorphous solid dispersions (ASD) utilizing casein proteins from bovine milk to create ethanol-free oral liquid...
- The National Institute of Child Health and Human Development awarded the University of Pennsylvania $465,870 on June 1, 2026, under the Child Health and Human Development Extramural Research Program (CFDA 93.865, Project Grant R01HD120540) to investigate postpartum maternal immune dynamics and viral disease outcomes. The research focuses on defining immune mechanisms underlying enhanced maternal resilience to severe viral infection during the postpartum period. The project includes two primary...
- The National Institute of Child Health and Human Development awarded the University of Pennsylvania $100,228 on November 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to support research into TRPML1 regulation and its role in lysosomal morphology and function. The research addresses knowledge gaps in lysosomal biology, focusing on how the transient receptor potential mucolipin 1 (TRPML1) ion channel regulates lysosomal function and morphology....
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded The Pennsylvania State University $150,594 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate customizable, feasible, and cost-effective dietary assessment methods for infants. The project will pilot and validate three novel infant-tailored dietary assessment methods designed to inform future clinical trials examining early-life...
- The National Institute of Child Health and Human Development awarded The Pennsylvania State University $120,399 on July 10, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a longitudinal, multi-method investigation of biobehavioral synchrony and hormonal correlates of parenting from pregnancy through toddlerhood. The research integrates functional near-infrared spectroscopy and microanalytic coding to assess neural and behavioral...
- The National Institute of Child Health and Human Development awarded $119,610 to the University of Pennsylvania on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop generalizable growth charts of thalamocortical development in early childhood. Thalamocortical bundles of white matter regulate critical periods of brain plasticity throughout development, and their disruptions have been implicated in common and debilitating psychiatric...
- The National Institute of Allergy and Infectious Diseases awarded Pennsylvania State University (Penn State Milton S. Hershey Medical Center) $267,704 on April 3, 2026, to develop and validate a lateral flow point-of-care device for detecting Paenibacillus thiaminolyticus in neonatal sepsis cases, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop and test a lateral flow assay based on monoclonal antibodies specific for pathogenic strains of...
The National Institute of Child Health and Human Development awarded Pennsylvania State University operating as Penn State Milton S. Hershey Medical Center $679,059 on September 3, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct research on thiamine supplementation as an intervention to prevent neurologic sequelae in infants with invasive bacterial infections. The research, titled "Thiamine for Recovery in Vulnerable Early-Life Infections (THRIVE)," addresses permanent serious complications following infant infections, including hearing loss, cerebral palsy, hydrocephalus, and neurocognitive impairment. The study comprises three integrated aims: baseline measurement of thiamine concentrations in whole blood and cerebrospinal fluid from hospitalized infants with and without invasive bacterial infections; a randomized controlled trial comparing neurodevelopmental outcomes at 18 months for infants receiving standard-of-care antibiotics alone versus antibiotics plus thiamine supplementation; and comparison of outcomes stratified by whether the infecting pathogen produces thiaminase. The primary outcome measure is neurodevelopment at 18 months, with secondary outcomes assessed at hospital discharge and 18 months. Performance occurs in Hershey, Pennsylvania. The period of performance runs through July 31, 2031. This is a project grant, the standard research funding mechanism under the NICHD extramural research portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $679.1k | 9/3/26 |